Expand OTLK Menu
OTLK MENU

OTLK Latest Press Releases

-- February 19, 2026 --

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland Globe Newswire 9:00 AM

-- February 17, 2026 --

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 8:05 AM

-- February 11, 2026 --

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter Globe Newswire 8:45 AM

-- January 6, 2026 --

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development Globe Newswire 8:35 AM

-- December 31, 2025 --

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD Globe Newswire 4:15 PM

-- December 26, 2025 --

Outlook Therapeutics Announces New Employment Inducement Grants Globe Newswire 5:00 PM

-- December 19, 2025 --

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 Globe Newswire 8:05 AM

-- November 24, 2025 --

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference Globe Newswire 9:05 AM

-- November 13, 2025 --

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Globe Newswire 8:30 AM

-- November 3, 2025 --

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 Globe Newswire 8:35 AM

-- September 29, 2025 --

Outlook Therapeutics Provides Update on Type A Meeting with FDA Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes